Update On New Commercial Models: ZS' View Of Charge Backs, Rebates And Flexibility
Pharmaceutical companies have been downsizing their sales forces and implementing new commercial models for several years in response to wide-ranging market changes, driven by growing payer influence and a lack of compelling new drugs. The size of the U.S. pharma sales force peaked in the second quarter of 2006 at 106,000, and fell to 91,000 by year-end 2008. It is expected to decline even further to 70,000 to 80,000 by year-end 2009, according to ZS Associates, a sales and marketing consulting firm.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth